- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Radiotherapy not always needed for elderly women with low-risk luminal A breast cancer
Elderly women with low-risk luminal A breast cancer can safely avoid radiotherapy with guidance from Ki67 proliferation marker screening, finds phase III LUMINA study. McMaster University researcher Timothy Whelan and his team has found that older women with early stage breast cancer may not need radiotherapy after undergoing surgery.
Whelan said that women 55 or older with stage one breast cancer displaying a specific biomarker pattern identifying the luminal A subtype can be effectively treated with just surgery and endocrine therapy. He presented research at the American Society of Clinical Oncology's annual meeting in Chicago on June 7.
His research team, working with the Ontario Clinical Oncology Group at the Hamilton Health Sciences, tracked 501 patients with luminal A breast cancer for five years post-surgery and found the recurrence of cancer in the breast was just 2.3 per cent without radiotherapy. This was roughly comparable with a 1.9 per cent risk this patient sample had of developing a new breast cancer in their other untreated breast.
Whelan said at this time patients with early stage breast cancer typically undergo radiotherapy courses of three to five weeks to reduce the risk of their cancer recurring.
"These findings are exciting because we have identified a certain group of patients who can avoid radiotherapy and its associated side effects and potentially change for the better medical practice around the treatment of breast cancer," said Whelan, a professor in the Department of Oncology at McMaster, a Canada Research Chair in Breast Cancer Research and a radiation oncologist for Hamilton Health Sciences.
"Radiotherapy has significant early side effects, including fatigue and skin irritation that can last for several weeks after the course is completed, and late side effects such as breast shrinkage and distortion that can affect quality of life and very rarely more serious complications such as heart disease and second cancers," he said.
"If we can avoid radiotherapy, so much the better. Not all cancers require the same level of often-invasive treatment. There is a very low risk group of breast cancers displaying the luminal A biomarker and they are not particularly aggressive."
He said the overall risk of cancer recurrence following breast-conserving surgery has decreased in recent years thanks to regular mammogram screening, improved surgical techniques and better systemic treatments.
Whelan said his research is now tracking patients with the luminal A variant of breast cancer for 10 years to learn more about treatment efficacy without the use of radiotherapy.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751